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REPORT
Biallelic Mutations in TBCD, Encoding the Tubulin
Folding Cofactor D, Perturb Microtubule Dynamics
and Cause Early-Onset Encephalopathy
Elisabetta Flex,1,18 Marcello Niceta,2,18 Serena Cecchetti,3 Isabelle Thiffault,4,5,6 Margaret G. Au,7
Alessandro Capuano,2 Emanuela Piermarini,2 Anna A. Ivanova,8 Joshua W. Francis,8
Giovanni Chillemi,9 Balasubramanian Chandramouli,10 Giovanna Carpentieri,1,11
Charlotte A. Haaxma,12 Andrea Ciolfi,2,13 Simone Pizzi,2 Ganka V. Douglas,14 Kara Levine,14
Antonella Sferra,2 Maria Lisa Dentici,2 Rolph R. Pfundt,12 Jean-Baptiste Le Pichon,15 Emily Farrow,4
Frank Baas,16 Fiorella Piemonte,2 Bruno Dallapiccola,2 John M. Graham, Jr.,7 Carol J. Saunders,4,5,6
Enrico Bertini,2 Richard A. Kahn,8 David A. Koolen,17 and Marco Tartaglia2,*
Microtubules are dynamic cytoskeletal elements coordinating and supporting a variety of neuronal processes, including cell division,
migration, polarity, intracellular trafficking, and signal transduction. Mutations in genes encoding tubulins and microtubule-associated
proteins are known to cause neurodevelopmental and neurodegenerative disorders. Growing evidence suggests that altered microtubule
dynamics may also underlie or contribute to neurodevelopmental disorders and neurodegeneration. We report that biallelic mutations
in TBCD, encoding one of the five co-chaperones required for assembly and disassembly of the ab-tubulin heterodimer, the structural
unit of microtubules, cause a disease with neurodevelopmental and neurodegenerative features characterized by early-onset cortical
atrophy, secondary hypomyelination, microcephaly, thin corpus callosum, developmental delay, intellectual disability, seizures, optic
atrophy, and spastic quadriplegia. Molecular dynamics simulations predicted long-range and/or local structural perturbations associated
with the disease-causing mutations. Biochemical analyses documented variably reduced levels of TBCD, indicating relative instability of
mutant proteins, and defective b-tubulin binding in a subset of the tested mutants. Reduced or defective TBCD function resulted in
decreased soluble a/b-tubulin levels and accelerated microtubule polymerization in fibroblasts from affected subjects, demonstrating
an overall shift toward a more rapidly growing and stable microtubule population. These cells displayed an aberrant mitotic spindle
with disorganized, tangle-shaped microtubules and reduced aster formation, which however did not alter appreciably the rate of cell
proliferation. Our findings establish that defective TBCD function underlies a recognizable encephalopathy and drives accelerated
microtubule polymerization and enhanced microtubule stability, underscoring an additional cause of altered microtubule dynamics
with impact on neuronal function and survival in the developing brain.

Microtubules are dynamic cytoskeletal elements required
for many cellular and developmental processes. Their function is particularly critical in neurons, where they coordinate proliferation and migration, maintain neuronal polarity, support intracellular trafficking, and contribute to
signal transduction.1 In neurons, their dynamic remodeling also contributes to the finely controlled events
required for neuronal differentiation, proper morphological and functional maturation, and the establishment
and maintenance of synaptic connections and plasticity.1,2 The structural unit of microtubules is the ab-tubulin heterodimer, whose assembly relies upon the CCT/TriC
complex, five tubulin cofactor (TBC) proteins (i.e., TBCA to
TBCE), and the small GTPase, ARL2.3,4 Mutations in genes

encoding tubulins and microtubule-associated proteins
have been reported to cause a wide spectrum of neurodevelopmental and neurodegenerative disorders.5,6 These mutations commonly affect tubulin dimer formation and/or
polymerization and reduce microtubule stability. Growing
evidence, however, suggests that altered microtubule dynamics can also lead to neurodegeneration.7 Here we
report that mutations in TBCD, encoding one of the five
co-chaperones required for assembly and disassembly of
the ab-tubulin heterodimer, underlie a previously unrecognized encephalopathy inherited as a recessive trait and exhibiting both neurodevelopmental and neurodegenerative
features, including developmental delay and profound
intellectual disability, seizures, progressive spasticity, optic
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Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen 1105, the Netherlands; 13Centro di Ricerca per gli
alimenti e la nutrizione, CREA, Rome 00178, Italy; 14GeneDx, Gaithersburg, MD 20877, USA; 15Department of Pediatrics, Children’s Mercy Hospitals, Kansas City, MO 64108, USA; 16Department of Genome Analysis, Academic Medical Center, Amsterdam 1105, the Netherlands; 17Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen 1105, the Netherlands
18
These authors contributed equally to this work
*Correspondence: marco.tartaglia@opbg.net
http://dx.doi.org/10.1016/j.ajhg.2016.08.003.
Ó 2016 American Society of Human Genetics.

962 The American Journal of Human Genetics 99, 962–973, October 6, 2016

atrophy, early-onset cortical atrophy associated with secondary hypomyelination, and thin corpus callosum. We
demonstrate that disease-causing mutations affect TBCD
synthesis, stability, and/or function and perturb microtubule dynamics, with an overall shift toward a more rapidly
growing and stable microtubule population.
Seven subjects from five unrelated families were included
in the study. Clinical data and biological material collection, use, and storage were obtained from the participating
families after written informed consent was provided, and
studies for each family were approved by the respective
institutional review boards. To identify the genetic cause
of a severe encephalopathy affecting two siblings
(F118_346 and F118_347) exhibiting early-onset cortical
atrophy, thinned corpus callosum, developmental delay,
intellectual disability, epilepsy, and spastic tetraplegia
(Figure 1 and Table S1), we performed whole-exome
sequencing (WES). Exome capture was conducted using
SureSelect Human All Exon v.4 (Agilent Technologies) on
genomic DNA extracted from circulating leukocytes of
the two siblings and their unaffected parents. Sequencing
data processing, annotation, and filtering were performed
using an in-house implemented pipeline which mainly
takes advantage of the Genome Analysis Toolkit (GATK
v.3.4) framework,8 following the GATK’s latest best practices, as previously reported.9–12 For sequencing statistics,
see Table S2. High-quality variants were filtered against
public databases (dbSNP142 and ExAC v.0.3) to retain
private and clinically associated variants, and annotated
variants with unknown frequency or having MAF <
0.1%, and occurring with a frequency < 2% in an in-house
WES variant database (approx. 600 population-matched
exomes). Functional annotation of variants was performed
using SnpEff v.4.1 and dbNSFP v.2.8.13,14 Autosomalrecessive transmission was considered as the most likely
inheritance model, and variant filtering and prioritization
revealed a homozygous missense change, c.3365C>T
(p.Pro1122Leu), in TBCD (tubulin-specific chaperone D)
(MIM: 604649, GenBank: NM_005993.4) as the only
strong candidate underlying the disease. Sanger
sequencing confirmed homozygosity for the variant in
each sibling (Figure S1). Biallelic TBCD variants were independently identified by WES in five additional subjects
with similar clinical features from four unrelated families
(Figure 1 and Table S1). In one family, matching was
facilitated by GeneMatcher.15 The oldest sibling,
CMH444, presented with focal epilepsy associated with
congenital spastic tetraplegia and cognitive deficits. Brain
MRI documented a thinned corpus callosum, cortical
brain atrophy, and white matter volume loss. His sister,
CMH445, presented with a similar constellation of symptoms, but with a relatively less severe phenotype. DNA
was prepared utilizing the KAPA Biosystems library preparation kit (KAPA Biosystems) followed by TruSeqExome
enrichment v.4 (Illumina). Read alignment and variant
calling, filtering, and prioritization were performed as previously published,16–18 using custom-developed software,

RUNES and VIKING. Variants were filtered to retain those
with predicted impact on transcript processing and protein-coding sequence having allele frequency < 1% in public and in-house databases. Among the identified genes
with variants compatible with a recessive mode of inheritance, TBCD emerged as the best candidate (Table S2). Similarly, matching was facilitated by GeneMatcher for subject
1455707. This child could not stand or sit independently.
She had absent speech, minimal movement, and some
response to noises and voices. Developmental delay and
microcephaly were first noted at 4 months. MRI at 6 and
12 months showed a thin corpus callosum with hypoplasia
of the rostrum and splenium and delayed myelination.
Exome sequencing was performed by GeneDx on exon targets isolated by capture using the Clinical Research Exome
kit (Agilent). Reads were aligned to the human genome
build hg19 and analyzed and interpreted using a customdeveloped analysis tool (Xome Analyzer) as previously
described.19 General assertion criteria for variant classification are publicly available on the GeneDx ClinVar submission page (submitter code: 26957). WES data analysis
did not identify any de novo variant, and filtering and
prioritization of the seven genes with biallelic variants
pointed out to c.686T>G (p.Leu229Arg) and c.3365C>T
(p.Pro1122Leu) in TBCD as the most promising diseasecausing candidates (Table S2). The fourth subject,
3641284, presented with generalized hypotonia, developmental delay, seizures, and marked cerebral atrophy at
8 months. At 3 years, he exhibited severe intellectual
disability with no speech or voluntary movement and a hypotonic tetraplegia dominated by a severe pure motor neuropathy. Finally, subject 6215546 was characterized by a
relatively more attenuated phenotype, exhibiting developmental delay, only incidental seizures during infancy, moderate cognitive deficits, dysarthria, very mild pyramidal
dysfunction of the arms, and marked hypertonic spastic
paraplegia of the legs. MRI indicated minor cortical atrophy
and thin corpus callosum. For both individuals, capture of
target sequences was performed using the SureSelect
Human All Exon v4 enrichment kit (Agilent Technologies)
and sequencing was outsourced (BGI). WES data were processed, annotated, and filtered using an in-house developed pipeline as previously reported.20 Candidates were
prioritized taking into account both the predicted functional impact of filtered variants and the biological relevance of individual genes. In both individuals, compound
heterozygosity for mutations in TBCD emerged as the most
likely events underlying the trait (Table S2).
All putative disease-causing variants were confirmed by
Sanger sequencing (Figure S1). With the exception of one
splice site change, all variants were missense nucleotide
substitutions affecting conserved residues among orthologs (Figure S2). Functional impact of variants was
analyzed by Combined Annotation Dependent Depletion
(CADD) v.1.3 and Database for Nonsynonymous SNPs’
Functional Predictions (dbNSFP) Support Vector Machine
(SVM) v.3.0 algorithms.21,22 All variants were predicted to
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Figure 1. Clinical Features of Subjects with Biallelic TBCD Mutations
(A) Features of affected subjects. Note microcephaly in subjects F118_346, F118_347, 3641284, and 1455707 and tetraplegia in F118_346
and F18_347.
(B) Brain MRIs of individuals F118_347 (8 months old; top left three panels) and F118_346 (2 years old; middle left three panels) showing
axial, sagittal, and coronal views (from the left). F118_347 exhibits diffuse prominence of the cortical sulci with thinned corpus callosum
and white matter volume loss with hypomyelination; the eldest sib exhibits more severe MRI features, with diffusely widened cortical
sulci and cerebellar foliae and enlargement of lateral and third ventricles. MRIs of subjects CMH445 (16 years old; top right two panels)
and CMH444 (13 years old; middle two right panels). In the former, diffuse prominence of the cortical sulci and cerebellar foliae with
mild enlargement of the lateral and third ventricles and thinned corpus callosum are documented. In the latter, a milder pattern is
observed, documenting a thin corpus callosum and partial white matter hypomyelination and mild cortical atrophy. MRIs of subjects
3641284 (3.5 years old; bottom three left panels) and 6215546 (17 years old; bottom right two panels). In the former, enlarged ventricles
and generalized atrophy of gray matter, thin corpus callosum, cerebellar vermis atrophy, and abnormal white matter T2 and FLAIR signal
hyperintensity due to severe secondary hypomyelination are observed. In the latter, slightly enlarged posterior lateral ventricles, mild
cortical atrophy, hypoplastic splenium of the corpus callosum, and ectopic neuropituitary are noted.

be deleterious and were either rare or not present in reference population databases (Table 1).
Major recurrent features in individuals with biallelic
TBCD mutations included developmental delay and profound intellectual disability, seizures, progressive spasticity, optic atrophy, cortical atrophy, and thin corpus cal-

losum. Microcephaly occurred in four subjects, and in
three individuals it was present at birth and correlated
with the time of onset and progression of atrophy. Quadriplegia was documented in all individuals. Four subjects
were never able to walk, and three of them never achieved
sitting or head control; those that attained walking
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Abbreviations are as follows: ND, not determined; hom., homozygous change; het., heterozygous change; P, paternally inherited; M, maternally inherited.
a
Nucleotide and amino acid positions refer to GenBank: NM_005993.4 (cDNA) and NP_005984.3 (protein).
b
Prediction based on CADD v.1.3 and dbSNP v.3.0 SVM.

26.2, 0.25; 26.0, 0.37
p.Leu229Arg, p.Pro1122Leu
het. (P), het. (M)
rs778417127 ExAc: 2.5 3 105,
rs755177846 ExAc: 3.3 3 105
7, 36
17: 80,739,512,
17: 80,896,008
1455707

c.686T>G, c.3365C>T

24.0, ND; 29.0, 0.64
ND, p.Thr374Met
het. (M), het. (P)
novel, novel
int7, 11
17: 80,739,598,
17: 80,765,517
6215546

c.771þ1_771þ10del,
c.1121C>T

27.2, 0.04; 32.0, 0.94
p.Ala626Thr, p.Arg377Gln
het. (P), het. (M)
novel rs764085684
ExAc: 8.2 3 107
20, 11
17: 80,863,883,
17: 80,765,526
3641284

c.1876G>A, c.1130G>A

29.2, 0.35; 20.8, 1.11
p.Thr994Met, p.Val1105Met
het. (P), het. (M)
novel rs764003906
ExAc: 1.6 3 105
32, 33
17: 80,887,366,
17: 80,895,956
CMH444 and
CMH445

c.2981C>T, c.3313G>A

26.0, 0.37
hom.
17: 80,896,008
F118_346 and
F118_347

c.3365C>T

36

rs755177846 ExAc: 3.3 3 105

p.Pro1122Leu

Funct. Impactb (CADD Score,
metaSVM Score)
Amino Acid Changea
Status
Annotation
Coding Exon
Nucleotide Changea
Genomic Coordinate
(hg19)
Subject(s)

List of the Identified TBCD Mutations Causing Early-Onset Encephalopathy
Table 1.

subsequently lost this ability because of severe and progressive spasticity. Five individuals had epileptic seizures;
peripheral motor axonal neuropathy was recorded in one
subject. MRI showed signs of cortical atrophy and a thin
corpus callosum in all subjects; this was associated with
secondary hypomyelination and cerebellar atrophy in
the most severely involved individuals. The clinical phenotype was relatively homogeneous, allowing validation
of the causative role of the identified TBCD missense
changes, even though variability in the onset and progression was observed. Of note, subject 6215546 presented an
attenuated phenotype, which correlated with the milder
perturbing effect of the p.Thr374Met substitution, while
the particularly severe condition recorded in individuals
F118_346 and F118_347 was associated with an extremely
reduced TBCD level (discussed below). Overall, we
consider this recessive condition caused by TBCD mutations as a disorder characterized by both neurodevelopmental and neurodegenerative features, in which the
less-severe phenotypes appear to be characterized by
early-onset neurodegeneration. The subjects’ clinical history, including delayed motor milestones, the progressive
nature of the disorder, brain MRI evidence of cortical atrophy and hypomyelination, followed later by cerebellar
atrophy, all seem to indicate that this condition is a neurodevelopmental disorder with evidence of slowly progressive neurodegeneration. This is further evidenced by the
presence of microcephaly in most affected individuals.
Of note, none of the affected individuals exhibited defects
of cortical development associated with altered neuronal
proliferation and migration, which is a common finding
among tubulinopathies.23
TBCD encodes one of the five co-chaperones participating in the assembly of a- and b-tubulin in tubulin heterodimers to be incorporated in microtubules.24 It is a large
(133 kDa) protein predicted to be predominantly a-helical
in structure and containing armadillo/HEAT repeats,
which mediate protein-protein interaction.25 The identified disease-associated variants mapped at different regions
of the protein, and to explore in silico their impact on
TBCD structure and function, we performed molecular dynamics (MD) simulations on the modeled structure of
native and mutant TBCD obtained by homology modeling
using SWISS-MODEL server (Figure S3). The starting model
was refined by geometry optimization followed by MD
simulations with Gromacs v.5.0.4 package, using the
gromos54a7.ff force field.26,27 The starting structure was
embedded in a dodecahedron box filled with SPC water
molecules,28 which extended up to 12 Å from the solute,
and counter ions were added to neutralize the overall
charge with Gromacs genion tool. After a long energy
minimization (10,000 iterations), the system was slowly
relaxed for 5 ns applying positional restraints (1,000 kJ
mol1 nm2) to the protein atoms, and an uncontrolled
MD simulation was protracted for 400 ns with a time
step of 2 fs. V-rescale temperature coupling was employed
to keep the temperature constant at 300 K.29 The
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Figure 2. Disease-Causing TBCD Mutations Affect TBCD Stability and Function
(A) Western blot (WB) analysis showing decreased level of TBCD in fibroblasts from affected individuals 3641284, 6215546, and
F118_346 compared to control cells (WT) (above). Levels of Myc-tagged TBCDp.Thr374Met (374), TBCDp.Arg377Gln (377), TBCDp.Ala626Thr
(626), and TBCDp.Pro1122Leu (1,122) mutants were confirmed to be variably reduced compared to wild-type TBCD (WT) by transient
expression experiments in HeLa and HEK293T cells (below).
(B) TBCDp.Thr374Met (374) and TBCDp.Arg377Gln (377) mutants display defective TBCD:b-tubulin:ARL2 complex formation. Constructs encoding the GST-tagged TBCD proteins were co-expressed with ARL2 in HEK293T cells and affinity purified, followed by GST cleavage.
Proteins were resolved by SDS-PAGE and stained with Coomassie blue.

simulation was performed enforcing periodic boundary
condition, and the Particle-Mesh Ewald method was
used for the treatment of long-range electrostatic interactions.30 Starting models for the mutant systems were
generated by introducing mutations in silico into a welequilibrated (after ~50 ns) snapshot of the wild-type
(WT) protein, using UCSF-Chimera software.31 In all cases,
the side chain orientation was chosen based on the best
rotamer that had the least/no steric clashes with the
neighboring residues. During the whole simulation time,
the secondary structure of the WT protein appeared very
stable; by contrast, all amino acid substitutions led to substantial long-range and/or local structural perturbations.
In most cases (i.e., TBCDp.Thr374Met, TBCDp.Arg377Gln,
TBCDp.Ala626Thr, TBCDp.Thr994Met, and TBCDp.Pro1122Leu), a
considerable decrease in structured residues due to transition from a helix to coil was observed, while reduced
flexibility at residues 836–910 occurred in all modeled
mutants (particularly evident in TBCDp.Leu229Arg and
TBCDp.Val1105Met) (Figure S3). Of note, all mutants exhibited a statistically significant reduction of the solvent
accessibility surface (SAS) (Figure S4). Maximum deviation
was observed for the modeled protein carrying the
p.Pro1122Leu substitution, which was associated with
the more severe clinical phenotype. Remarkably, visualization of positive and negative electrostatic potential isosurfaces showed variable perturbations in all mutants (Figures
S5 and S6), with more dramatic changes involving proteins
carrying the p.Leu229Arg, p.Arg377Gln, p.Thr994Met,
and p.Val1105Met substitutions. Overall, these in silico
simulations consistently predicted a variable but relevant
impact of all amino acid substitutions on protein structure
and folding.
To analyze the functional impact of variants directly, we
first evaluated whether they affected the level of the

TBCD protein in skin fibroblasts obtained from three unrelated subjects (F118_346, 3641284, and 6215546) cultured
in Dulbecco’s modified Eagle’s medium supplemented with
10% heat-inactivated fetal bovine serum (EuroClone).
Western blot (WB) analysis performed on cell lysates,
using a previously validated anti-TBCD antibody,32 followed by visualization of the immunoreactive proteins by
enhanced chemiluminescence (Millipore) documented
variably reduced levels of TBCD protein, with a dramatic
decrease particularly occurring in fibroblasts homozygous
for the p.Pro1122Leu substitution (Figure 2A). To confirm
these findings, the single-nucleotide changes resulting
in the p.Thr374Met, p.Arg377Gln, p.Ala626Thr, and
p.Pro1122Leu substitutions were introduced by sitedirected mutagenesis in a C-terminal Myc-DDK-tagged
human TBCD cDNA cloned in pCMV6-Entry vector
(RC200381, Origene), and each construct was transiently
transfected (Fugene 6, Promega) in HEK293T. At 48 hr after
transfection, cells were lysed and the level of TBCD was assessed by immunoblotting with an anti-Myc antibody (Cell
Signaling), which reproduced this variable destabilization
of each of these mutants (Figure 2A). Similar results were obtained in transiently transfected HeLa cells. Treatment of
transfected cells with cycloheximide (20 mg/mL), a protein
synthesis inhibitor, documented a pronounced decay of
protein level for the TBCDp.Pro1122Leu mutant (Figure S7),
confirming the impact of mutation on protein stability.
TBCD localizes at the centrosome, the major microtubule-organizing center,32,33 and confocal immunofluorescence analysis was performed to evaluate possible altered
subcellular localization of TBCD mutants. Fibroblasts
were seeded at the density of 20 3 103 in 24-well cluster
plates onto 12-mm cover glasses and treated with thymidine and nocodazole (Sigma). Fixed cells were stained
with anti-TBCD and anti-g-tubulin (Sigma) antibodies,
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the respective fluorochrome-conjugated secondary antibodies (Invitrogen), and DAPI. Cells stained only with
the fluorochrome-conjugated secondary antibodies were
used to set up acquisition parameters, and signals from
the different fluorescent probes were taken in sequential
scanning mode, using a TCS SP2 AOBS apparatus (Leica
Microsystems). In all tested cells from affected subjects,
co-localization of TBCD mutants with g-tubulin, used as
a centrosome marker, was documented (Figure S8), indicating the retention of this feature of TBCD function.
TBCD is known to bind to b-tubulin and ARL.34 Based
on the recessive transmission of the disorder and the
variable reduced level of individual TBCD mutants, we hypothesized a hypomorphic/loss-of-function role for the
identified disease-causing variants possibly affecting
proper interaction of TBCD with its binding partners.
To test this hypothesis, we co-expressed each diseaseassociated TBCD cDNA encoding the TBCDp.Thr374Met,
TBCDp.Arg377Gln, and TBCDp.Ala626Thr mutants as GSTfusion proteins,35 along with the binding partner ARL2,
in HEK293T cells to allow ready purification and analysis
of complex formation. Soluble proteins were obtained by
centrifugation of cell lysates and complexes were purified
using Glutathione Sepharose 4B (GE 17-0756-01) beads
prior to removal of the GST, by addition of purified
TEV protease. SDS-PAGE and Coomassie blue staining
showed that WT TBCD and TBCDp.Ala626Thr purified
as complexes of TBCD:b-tubulin:ARL2 in the expected
1:1:1 ratio (Figure 2B). In contrast, TBCDp.Thr374Met and
TBCDp.Arg377Gln co-purified with substantially reduced
amounts of b-tubulin, despite retention of ARL2 binding,
indicating specific loss in b-tubulin binding. All purified
complexes were then analyzed using a dye binding
(ThermoFluor) assay to determine thermal stability.
Thermal denaturation curves were generated using
StepOnePlus Real-Time temperature block by mixing
TBCD (20 mL, final concentration 1 mg/mL protein) with
2 mL 1:100 dilution of SYPRO Orange dye (S5692, Sigma).
Fluorescence emission (603 nm) was determined using
excitation at 488 nm every 2 min for 2 hr over the range
of 25 C–98 C, and the melting and plateau phases of
collected data were analyzed with GraphPad Prism 6 software. The curves were fit to a Boltzmann sigmoidal equation to determine the Tm (inflection point) of each sample.
Data obtained from four replicates of each protein, from
two independent preparations of each, indicated that the
TBCDp.Thr374Met and TBCDp.Arg377Gln proteins displayed a
clearly decreased stability, as evident by the statistically significant lower Tm compared to the WT protein (Table S3).
This decreased stability is predicted to be a consequence
of the paucity of b-tubulin in each of these preparations,
and consistently supported a loss-of-function role of disease-causing TBCD variants. Overall, the structural and
biochemical characterization of disease-causing TBCD
mutations consistently predicted a substantial impact on
protein structure and folding, resulting in variable reduced
stability and defective function of TBCD mutants.

Perturbed TBCD levels have been documented to affect
assembly and disassembly of ab-tubulin polymers.36,37
Because proper microtubule dynamics is required for correct plasticity of cytoskeletal components38 and depends
upon a tightly controlled balance of assembly/disassembly
of ab-tubulin polymers, we then examined the impact of
TBCD mutations on the microtubule array. The amounts
of total, soluble, and polymerized tubulin pools were determined in fibroblasts from affected individuals and control
subjects. Tubulin pools were extracted as described.39 After
12% SDS-PAGE, equal volumes of each pool were analyzed
by WB analysis using monoclonal anti-a-tubulin (Sigma
cat# T5168, RRID: AB_477579) antibodies and revealed
by a horseradish peroxidase-conjugated goat anti-mouse
secondary antibody (Rockland). Analyses revealed that total a-tubulin levels (Figure 3A) were not significantly
altered in fibroblasts from affected individuals, though soluble pools comprised a smaller tubulin fraction, indicating
an enhanced microtubule stability and a reduction of the
pool of tubulin dimers available for polymerization. In
addition to its role in building the core structure of microtubules, TBCD has been proposed to modulate microtubule dynamics by promoting tubulin disassembly.37 To
further explore the impact of mutations on microtubule
dynamics, the kinetics of tubulin polymerization was assessed in primary fibroblasts from affected individuals
and control subjects treated with 10 mM nocodazole
(30 min, 37 C) to completely depolymerize the microtubules. After drug washout, recovery was allowed for 5, 10,
20, and 30 min. Immunofluorescence analysis was performed on fixed cells after staining with a-tubulin antibody (Abcam) followed by the appropriate secondary antibody (Invitrogen) and DAPI. Compared to what observed
in treated control fibroblasts, microtubule re-polymerization was accelerated in cells from subjects with biallelic
TBCD mutations (Figure 3B), consistent with these mutations being loss of function or hypomorphic, as TBCD
overexpression has been demonstrated to prevent the
growth of microtubules in the same assay.37 Together,
these findings indicated that disease-associated defective
TBCD function results in a shift toward a more rapidly
growing and perhaps more stable microtubule population.
At the centrosome, TBCD is required for initiation of
microtubule growth and organization of the mitotic
spindle.32,33 To further examine the impact of defective
TBCD function on microtubule rearrangement and dynamics, confocal analysis was directed to evaluate possible
perturbation on mitosis and microtubule spindle configuration in fibroblasts from affected subjects. After 24 hr of
culture in complete medium, cells were treated with
2 mM thymidine (24 hr), washed with PBS, and treated
with 100 ng/mL nocodazole (12 hr). After recovery
(120 min), cells were fixing every 15 min using PHEMO
buffer for 10 min at room temperature24 and stained
with pericentrin (Abcam), g-tubulin (Sigma), b-tubulin
(Sigma), and/or a-tubulin (Abcam) antibodies, followed
by the appropriate secondary antibodies (Invitrogen) and
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Figure 3. Defective TBCD Function Impacts Microtubule Dynamics
(A) Increased levels of polymerized a-tubulin in fibroblasts with biallelic mutations in TBCD. Representative western blots (WB) of total
(T), soluble (S), and polymerized (P) pools of a-tubulin in untreated cells during interphase (left) and synchronized cells during mitosis
(right). Equal amounts of proteins from both fractions were loaded onto SDS-PAGE and analyzed by WB probing with anti-a-tubulin
antibody. Densitometry is reported. Data are expressed as means 5 SD; *p < 0.05; **p < 0.01; ***p < 0.001.
(B) Accelerated microtubule re-polymerization in primary fibroblasts obtained from subjects with biallelic TBCD mutations. Representative confocal microscopy analysis of fibroblasts from affected subjects after nocodazole treatment showing accelerated microtubule repolymerization compared to control cells (left). Fixed cells were stained with anti-a-tubulin antibody (red) and DAPI (blue). The scale bar
(47 mm) is the same for all panels. Quantification of total fluorescence normalized on cell number, referred to the exponential phase of repolymerization (5 to 20 min), is also shown (right).

DAPI. These time-course experiments on synchronized
cells reveled altered spindle structure in all fibroblast lines
expressing biallelic TBCD mutations (Figure 4). Specifically, these cells exhibited disorganized, tangle-shaped
mitotic microtubules, with markedly reduced aster formation. Moreover, progression of mitosis appeared delayed,
possibly due to a transient blockade occurring during spindle formation. Aberrant spindle morphology was associated with significantly larger centrosomes and enhanced
g-tubulin and pericentrin signals (Figure S9). Of note, the
observed spindle anomalies did not alter significantly the
rate of fibroblast proliferation, as demonstrated by XTTbased cell proliferation assay (Roche Molecular Biochemicals) (Figure S10).
Here we established that biallelic hypomorphic/inactivating mutations in TBCD profoundly impact microtubule
dynamics and cause an early-onset and severe encephalopathy. TBCD is one of the five tubulin-specific chaperones
that function downstream of the cytosolic chaperonin
complex, mediating the reversible assembly of the a/
b-tubulin heterodimer.34,40 The protein also modulates

microtubule dynamics by sequestering b-tubulin from
GTP-bound a/b-tubulin heterodimers.37 More recently,
TBCD has been reported to localize at centrosomes and
Fleming bodies and to be required for the assembly and
maintenance of the mitotic spindle, microtubule retraction during cytokinesis, and cell abscission.32,33 Moreover,
TBCD has been shown to participate in centriolar and
ciliary basal body assembly, strongly suggesting a more
wider role in processes linked to microtubule nucleation.41,42 In contrast with the involvement of this protein
in such diverse fundamental cellular processes with relevance for diverse cell lineages, the major clinical features
associated with TBCD mutations appear to be almost
restricted to neurons, which suggests a specific and stringent dependence of these cells for proper TBCD function.
Consistent with the present findings, a recent study provided evidence that loss of TBCD in Drosophila results in
ectopic arborization of dendrites and axonal degeneration.43 Of note, overexpression of TBCD was also associated with microtubule disruption and ectopic dendrite
arborization, indicating that proper TBCD function is
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Figure 4. Defective TBCD Function Affects the Mitotic Spindle
Confocal microscopy analysis was performed in synchronized skin fibroblasts from subjects with biallelic TBCD mutations and control
cells. Images are representative of each stage of the cell cycle. Cells were stained using antibodies against pericentrin (red, centrosome
marker) and b-tubulin (green, marker for microtubules and mitotic spindle); chromosomes are DAPI stained (blue). Scale bars represent
6 mm.

crucial for in vivo neuronal morphogenesis. TBCD was
also shown to physically interacts with the intracellular
domain of Down syndrome cell adhesion molecule
(Dscam),43 a neuronal adhesion molecule that is highly expressed in the central nervous system during development
and is implicated in dendritogenesis, axonal outgrowth,
neuron-to-neuron recognition events, and neural circuit
formation.44
Although mutations affecting TBCA (MIM: 610058),
TBCB (MIM: 601303), and TBCC (MIM: 602971) have
not been associated with human disease thus far, biallelic
inactivating mutations in TBCE (MIM: 604934) have
been shown to underlie hyperparathyroidism-retardation-dysmorphism syndrome (MIM: 241410) and KennyCaffey syndrome (MIM: 244460).45 Interestingly, substitution at the last residue of Tbce (p.Trp524Gly) has been

documented to cause a nonsyndromic motor neuropathy
in mice resulting from decreased stability of the Tbce
mutant protein and associated with a reduced number of
microtubules suggested to originate from defective
stabilization.46 In line with this finding, we recently
identified a different hypomorphic missense mutation in
TBCE (p.Ile1155Asn) occurring at the compound heterozygous/homozygous state in subjects exhibiting earlyonset neurodegenerative encephalopathy with distal
spinal muscular atrophy.66 In these individuals, clinical
features resemble the phenotype of mice homozygous for
the p.Trp524Gly substitution and are associated with
reduced TBCE levels and altered tubulin polymerization.
These data indicate that, differently from the truncating
TBCE mutations described to perturb developmental
processes, partial retention of TBCE function results in
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neurodegeneration also in humans, which is consistent
with the present findings indicating both neurodevelopmental and neurodegenerative components associated
with mutations in TBCD. Based on these findings, we
expect that complete loss of TBCD function might result
in a particularly severe neurodevelopmental disorder.
Consistently, the present data suggest the occurrence of genotype-phenotype correlations, with the onset, progression, and overall severity of the phenotype linked to the
relative functional impact of mutations. Co-existence of
neurodevelopmental and neurodegenerative components
has previously been documented in other encephalopathies, such as pontocerebellar hypoplasia (PCH) caused
by mutations in EXOSC3 (MIM: 606489), TSEN54 (MIM:
608755), TSEN34 (MIM: 608754), TSEN15 (MIM:
608756), and TSEN2 (MIM: 608753) that are early-onset
neurodevelopmental disorders but are also associated
with signs of neurodegeneration after birth.47–49 Similarly
to what was observed in subjects with biallelic TBCD mutations, MRI profiles in these disorders do not show signs
of brain malformations, such as cortical dysplasia or
simplified gyral pattern, but include brain cortical and
cerebellar atrophy associated to PCH as predominant features. Hypomyelination was also observed to occur in subjects with TBCD mutations, which does not appear to be a
primary event since the early signs of brain cortical and
cerebellar atrophy suggest a primary neuronal involvement driving secondary white matter hypomyelination
and loss. Regarding this specific aspect, the condition appears similar to aspartate-glutamate carrier 1 deficiency
(MIM: 612949), a recessive encephalopathy caused by mutations in SLC25A12 (MIM: 603667),50 which was originally considered as a primary hypomyelination disorder
but later recognized as being characterized by a primary
neuronal cortical involvement with secondary hypomyelination.51 Another surrogate argument that would exclude
primary hypomyelination in TBCD mutation-related encephalopathy is the finding of low levels of N-acetylaspartate (NAA) by MRS in CMH445 and 3641284, the only
subjects included in this study for whom this information
was available, since NAA is generally characterized by
normal to increased levels by MRS in primary hypomyelination disorders due to abnormal raised levels of N-acetylaspartylglutamate.52,53 Additional individuals with
TBCD mutations will be necessary to characterize more
accurately the nature of this disorder as well as to more
precisely appreciate the extent of clinical variability associated with defective TBCD function.
Aberrant microtubule organization has been documented to underlie neurodevelopmental disorders.54,55
For example, mutations in TUBB3 causing malformations
in cortical development impair proper a/b-tubulin heterodimer formation and destabilize microtubules.56 Emerging
evidence supports the view that altered microtubule dynamics can also underlie or contribute to neurodegenerative disorders.7 Increased microtubule depolymerization
and defective microtubule assembly as a result of altered

function of the microtubule-associated protein Tau,
encoded by MAPT (MIM: 157140), has been proposed to
play a relevant role in Alzheimer disease.57 Similarly, neurite defects occurring in Parkinson disease have been attributed to increased microtubule depolymerization,39,58 and
toxins that lead to parkinsonism alter microtubule dynamics, causing a decrease in length and number of microtubules.59,60 Accumulating evidence also indicates that
disruption of presynaptic microtubules generally precede
synapse degeneration.61 Of note, similarly to what was
observed for the presently identified phenotype resulting
from biallelic mutations in TBCD, hyper-stabilization of microtubules has been shown to result in neurodegeneration,
as in the case of autosomal-dominant spastic paraplegia
type 4 (SPG4 [MIM: 182601]), a disease characterized by
the degeneration of corticospinal tracts and caused by
heterozygous mutations in SPG4, encoding the microtubule-severing enzyme spastin.62 In this progressive axonal
degeneration disorder, defective spastin function results
in a local accumulation of stable microtubules enriched in
detyrosinated a-tubulin.63 Remarkably, the degenerative
phenotype could be partly rescued in a SPG4 mouse model
by treatment with nocodazole,64 strongly indicating hyperstability and reduced dynamics as the event triggering
neuronal degeneration also in this disorder65 and providing
insights on possible therapeutic strategies.
In summary, we have recognized a previously unappreciated neurodevelopmental disorder with evidence of acquired hypomyelination and neurodegenerative features,
which is caused by defective TBCD function and associated with aberrant microtubule dynamics. These findings
further emphasize the relevant role of TBCD in modulating
stability and polymerization of microtubules and disclose
a novel mechanism driving accelerated polymerization
and enhanced stability of this cytoskeletal component
with dramatic impact on neuronal function and survival
in developing brain.
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C., Delga, S., Roblot, N., Lefèvre, J., Job, D., et al. (2013). Microtubule-targeting drugs rescue axonal swellings in cortical neurons from spastin knockout mice. Dis. Model. Mech. 6, 72–83.
Evans, K.J., Gomes, E.R., Reisenweber, S.M., Gundersen, G.G.,
and Lauring, B.P. (2005). Linking axonal degeneration to
microtubule remodeling by Spastin-mediated microtubule
severing. J. Cell Biol. 168, 599–606.
Sferra, A., Baillat, G., Rizza, T., Barresi, S., Flex, E., Tasca, G.,
D’Amico, A., Bellacchio, E., Ciolfi, A., Caputo, V., et al.
(2016). TBCE mutations cause early-onset progressive encephalopathy with distal spinal muscular atrophy. Immunity
45. Published online September 22, 2016. http://dx.doi.org/
10.1016/j.ajhg.2016.08.006.

The American Journal of Human Genetics 99, 962–973, October 6, 2016 973

